Ovarian cancer has no validated screening test, and approximately 80% of cases are diagnosed at Stage III or IV. The survival contrast tells the rest of the story: five-year relative survival is 92% at Stage I and 27% at Stage III or IV. With 21,010 new diagnoses and 12,450 deaths projected in the United States in 2026, and roughly half of patients aged 65 or older at diagnosis, the primary care role is not screening — it is recognition. Bloating, pelvic discomfort, early satiety, and urinary urgency are the signals, and acting on them promptly is where outcomes are shaped.
AAVBC's Ovarian Cancer Quick Reference Guide gives primary care clinicians a structured reference for early recognition, diagnostic workup, and longitudinal documentation of ovarian cancer. It covers alarm symptom thresholds, hereditary risk assessment, ICD-10 laterality and site coding, metastatic site documentation, BRCA and PARP inhibitor documentation, and MEAT documentation standards — grounded in current NCCN and SGO guideline evidence.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of ovarian cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Ovarian cancer has no validated screening test, and approximately 80% of cases are diagnosed at Stage III or IV. The survival contrast tells the rest of the story: five-year relative survival is 92% at Stage I and 27% at Stage III or IV. With 21,010 new diagnoses and 12,450 deaths projected in the United States in 2026, and roughly half of patients aged 65 or older at diagnosis, the primary care role is not screening — it is recognition. Bloating, pelvic discomfort, early satiety, and urinary urgency are the signals, and acting on them promptly is where outcomes are shaped.
AAVBC's Ovarian Cancer Quick Reference Guide gives primary care clinicians a structured reference for early recognition, diagnostic workup, and longitudinal documentation of ovarian cancer. It covers alarm symptom thresholds, hereditary risk assessment, ICD-10 laterality and site coding, metastatic site documentation, BRCA and PARP inhibitor documentation, and MEAT documentation standards — grounded in current NCCN and SGO guideline evidence.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of ovarian cancer — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
